文献速递眼底病与葡萄膜炎青光眼

前列腺素EP2受体与有晶状体眼小梁切除术后黄斑囊样水肿

Prostaglandin EP2 Receptor and Cystoid Macular Edema in Phakic Posttrabeculectomy Eyes.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

该回顾性病历回顾分析了某三级医疗中心2023年3月1日至2024年3月31日期间使用0.002%奥米帕格异丙基(OMDI)滴眼液的有晶状体眼患者,其中836例有晶状体眼患者中86例有小梁切除史,6例患者(8眼)发生黄斑囊样水肿(CME),均发生于开始治疗后的6至11个月。停用OMDI后28至91天视力恢复至6/6(20/20)至数指,随访5.5至12个月无复发;作者结论认为有小梁切除史的有晶状体眼患者开始OMDI后可发生CME,需进一步研究以了解该关联的程度和危险因素。

要点

  • 836例有晶状体眼患者使用OMDI,其中86例有小梁切除史,6例患者(8眼)发生CME,均在治疗开始后6至11个月出现。
  • CME发生后最佳矫正视力(翻滚E视力表)下降0至3行,3眼仅停用OMDI即恢复,3眼加用局部非甾体抗炎药,2眼需全身糖皮质激素。
  • 停用OMDI后28至91天视力恢复至6/6(20/20)至数指,CME消退后随访5.5至12个月未见复发。

核心结论

  • 有晶状体眼且有小梁切除史的患者在开始OMDI后可能发生黄斑囊样水肿。
  • 作者认为需进一步研究以了解该关联的程度及危险因素。

研究设计与样本

  • 回顾性病历回顾,纳入某三级医疗中心2023年3月1日至2024年3月31日期间在机构引入OMDI滴眼液后接受OMDI治疗的患者。
  • 共836例有晶状体眼患者接受OMDI治疗,其中86例有小梁切除史;数据于2024年12月6日分析。
  • 暴露为0.002%奥米帕格异丙基(OMDI)滴眼液,每日一次。

主要发现

  • 6例有小梁切除史的患者(8眼)发生CME,年龄范围41至61岁(中位数52.5岁),均发生于开始治疗后的6至11个月。
  • 研究期间,OMDI开始后随访不足6个月者366例,6至不足12个月者419例,12个月及以上者51例。
  • CME发生后最佳矫正视力(翻滚E视力表,基线范围6/6[20/20]至数指)下降0至3行。
  • 3眼接受局部非甾体抗炎药治疗,2眼需全身糖皮质激素,3眼仅停用OMDI即恢复。
  • CME消退后视力范围为6/6(20/20)至数指,时间为停用OMDI后28至91天;CME消退后随访5.5至12个月,期间未见复发。

局限性

  • 原文结论指出需进一步研究以了解该关联的程度及危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Omidenepag isopropyl (OMDI), a prostaglandin EP2 receptor agonist, effectively reduces intraocular pressure but has a known risk of cystoid macular edema (CME), particularly in pseudophakic and aphakic eyes. Its safety profile in patients with phakic eyes, especially those with prior glaucoma surgery, warrants clarification. OBJECTIVE: To provide clinical characteristics and disease course of CME associated with OMDI use in patients with phakic eyes. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective medical record review of patients at a tertiary medical center seen between March 1, 2023, and March 31, 2024. The study included patients who were treated with OMDI following the introduction of OMDI eye drops at the institution. Data were analyzed on December 6, 2024. EXPOSURES: Topical OMDI ophthalmic solution, 0.002%, administered once daily. MAIN OUTCOMES AND MEASURES: Medical records were assessed on December 6, 2024, to characterize clinical findings before and after onset of OMDI-related CME, including ophthalmic examinations, optical coherence tomography (OCT) imaging findings, and treatment strategies, as well as time to anatomic recovery and visual acuity outcomes. RESULTS: A total of 836 patients with phakic eyes were treated with OMDI, of whom 86 had a history of trabeculectomy. CME developed in 8 eyes from 6 patients with prior trabeculectomy (age range, 41-61 years; median, 52.5 years), all occurring between 6 and 11 months after treatment initiation. During the study, the follow-up period after OMDI initiation was less than 6 months in 366 patients, 6 to less than 12 months in 419 cases, and 12 months or more in 51 patients. Baseline visual acuities with correction (range, 6/6 [20/20] to counting fingers), measured with the tumbling E chart, declined by 0 to 3 lines following CME onset. Three eyes received topical nonsteroidal anti-inflammatory drug treatment, 2 eyes required systemic corticosteroids, and 3 eyes recovered by discontinuing OMDI alone without additional therapy. Visual acuities, after CME resolved, ranged from 6/6 (20/20) to counting fingers at 28 to 91 days after discontinuing OMDI. Among the CME cases, postresolution follow-up ranged from 5.5 to 12 months, with no recurrence observed during this period. CONCLUSIONS AND RELEVANCE: Cystoid macular edema can develop after initiating OMDI in patients with phakic eyes with a history of trabeculectomy prior to initiating OMDI. Further studies would be needed to understand the magnitude of this association and risk factors for this finding.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cheng MH, Hwang DK, Liu CJ, et al. Prostaglandin EP2 Receptor and Cystoid Macular Edema in Phakic Posttrabeculectomy Eyes. JAMA Ophthalmol. 2025. PMID: 40773215. doi:10.1001/jamaophthalmol.2025.2490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。